Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations:

None

PI Accessory Mutations: None
PR Other Mutations: V11P

V11P • T12V • I13S • K14R • I15L • G16E • K20R • E35D • M36I • R41K • R57K • L63V • E65D • H69K • L89M

Protease Inhibitors

atazanavir/r (ATV/r) Susceptible darunavir/r (DRV/r) Susceptible fosamprenavir/r (FPV/r) Susceptible indinavir/r (IDV/r) Susceptible lopinavir/r (LPV/r) Susceptible nelfinavir (NFV) Susceptible saquinavir/r (SQV/r) Susceptible tipranavir/r (TPV/r) Susceptible

PR comments

Other

K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

No drug resistance mutations were found for PI.

Mutation scoring; PR

Drug resistance interpretation: RT

NRTI Mutations: E44D

NNRTI Mutations: K103N

RT Other Mutations: E28K • V35T • T39D • K102Q • D121H • K122E • K173T • Q174K • D177E • V179I • T200A • I202V • Q207A • R2115 • K219X • V245Q • E248K • K249Q • N255M • D256T • I257Y • Q258R • A259-260 • V261X • G262S • K263R • L264N • N265K • W266L • A267G • A272P • V276" • K277A • Q278T • L279Y • C280V • K281R • R284S

Nucleoside	Reverse	Transcriptase	Inhibitors

abacavir (ABC)

zidovudine (AZT)

Susceptible

stavudine (D4T)

didanosine (DDI)

emtricitabine (FTC)

lamivudine (3TC)

tenofovir (TDF)

Susceptible

Susceptible

Susceptible

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

efavirenz (EFV)

etravirine (ETR)

nevirapine (NVP)

rilpivirine (RPV)

Susceptible

High-Level Resistance

Susceptible

Susceptible

RT comments

NRTI

E44D is a relatively non-polymorphic accessory mutation; E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs.

NNRTI

K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EPV susceptibility. It is the most commonly transmitted DRM.

Other

Mutation scoring: RT

V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

Rule	DOR ÷	EFV ÷	ETR ÷	NVP ≑	RPV ≑	
K103N	0	60	0	60	0	

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)